$17.12
0.110.65%
Pre-Market: 4:21 PM EDT
15 minutes delayed
Comments
Loading...
Cartesian Therapeutics
RNACNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Cartesian Therapeutics (NASDAQ:RNAC) Stock, Analyst Ratings, Price Targets, Forecasts
Cartesian Therapeutics Inc has a consensus price target of $42.6 based on the ratings of 6 analysts. The high is $49 issued by HC Wainwright & Co. on July 3, 2024. The low is $39 issued by Leerink Partners on April 23, 2024. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Canaccord Genuity on July 8, 2024, July 3, 2024, and July 3, 2024, respectively. With an average price target of $44.67 between Needham, HC Wainwright & Co., and Canaccord Genuity, there's an implied 160.90% upside for Cartesian Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Canaccord Genuity
Mizuho
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Cartesian Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/08/2024 | Buy Now | 145.33% | Needham | Gil Blum | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2024 | Buy Now | 186.21% | HC Wainwright & Co. | Mitchell Kapoor | $54 → $49 | Maintains | Buy | Get Alert |
| 07/03/2024 | Buy Now | 151.17% | Canaccord Genuity | John Newman | $38 → $43 | Maintains | Buy | Get Alert |
| 07/02/2024 | Buy Now | — | Oppenheimer | Matthew Biegler | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 07/01/2024 | Buy Now | 145.33% | Needham | Gil Blum | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 192.06% | Oppenheimer | Matthew Biegler | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 215.42% | HC Wainwright & Co. | Mitchell Kapoor | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2024 | Buy Now | 192.06% | Oppenheimer | Matthew Biegler | $50 → $50 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | 192.06% | Oppenheimer | Matthew Biegler | → $50 | Initiates | → Outperform | Get Alert |
| 05/24/2024 | Buy Now | 133.64% | Mizuho | Uy Ear | → $40 | Initiates | → Buy | Get Alert |
| 05/23/2024 | Buy Now | 215.42% | HC Wainwright & Co. | Mitchell Kapoor | → $54 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 215.42% | HC Wainwright & Co. | Mitchell Kapoor | → $54 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 145.33% | Needham | Gil Blum | → $42 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 215.42% | HC Wainwright & Co. | Mitchell Kapoor | $54 → $2 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | 127.8% | Leerink Partners | Thomas Smith | → $39 | Initiates | → Outperform | Get Alert |
| 04/10/2024 | Buy Now | 145.33% | Needham | Gil Blum | → $42 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 145.33% | Needham | Gil Blum | → $42 | Initiates | → Buy | Get Alert |
| 03/18/2024 | Buy Now | -88.32% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2024 | Buy Now | -88.32% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | -88.32% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2024 | Buy Now | -88.32% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Assumes | → Buy | Get Alert |
FAQ
What is the target price for Cartesian Therapeutics (RNAC) stock?
The latest price target for Cartesian Therapeutics (NASDAQ:RNAC) was reported by Needham on July 8, 2024. The analyst firm set a price target for $42.00 expecting RNAC to rise to within 12 months (a possible 145.33% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cartesian Therapeutics (RNAC)?
The latest analyst rating for Cartesian Therapeutics (NASDAQ:RNAC) was provided by Needham, and Cartesian Therapeutics reiterated their buy rating.
When was the last upgrade for Cartesian Therapeutics (RNAC)?
There is no last upgrade for Cartesian Therapeutics
When was the last downgrade for Cartesian Therapeutics (RNAC)?
The last downgrade for Cartesian Therapeutics Inc happened on July 2, 2024 when Oppenheimer changed their price target from N/A to N/A for Cartesian Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Cartesian Therapeutics (RNAC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cartesian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cartesian Therapeutics was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.
Is the Analyst Rating Cartesian Therapeutics (RNAC) correct?
While ratings are subjective and will change, the latest Cartesian Therapeutics (RNAC) rating was a reiterated with a price target of $42.00 to $42.00. The current price Cartesian Therapeutics (RNAC) is trading at is $17.12, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.